Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Japan Approves JCR Pharma’s Cell-Based Acute GVHD Treatment
JCR Pharmaceuticals said on September 18 that its human mesenchymal stem cell-based therapy, Temcell HS Inj., has won approval in Japan for acute graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. Temcell, the first allogeneic regenerative medicine product approved in…
To read the full story
Related Article
- JCR to Launch Cell Therapy for Post-Transplant Complication in February
November 30, 2015
- Drug Pricing Organization to Price JCR’s Cell Therapy Temcell
October 1, 2015
- PAFSC Committee Recommends Approval for 2 Regenerative Medicine Products
September 4, 2015
BUSINESS
- Chugai Licenses RAF-MEK Molecular Glue to InxMed
September 30, 2026
- OB-GYN Chief Hopes for April 2027 NIP Addition of RSV Antibodies
September 30, 2026
- Japan Needs to Boost COVID Vaccine Uptake, Expert Says
September 30, 2026
- Toho, Reprocell Tie Up on Cell Therapy Distribution in Japan
September 30, 2026
- Marubeni Pharma Launches OAB Drug Gemtesa in Taiwan
September 29, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…